Compare GSK plc (GSK) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tempus AI — how do they compare? GSK plc trades at $50.32 (market cap $102.60B), while Tempus AI trades at $54.98 (market cap $10.05B). The key difference: GSK plc is far larger — about 10.2× Tempus AI's market cap, and GSK plc pays a 3.57% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| GSK | TEM | |
|---|---|---|
Market Cap | $102.60B | $10.05B |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $103.25 |
52-Week Low | $38.22 | $41.55 |
Enterprise Value | $123.04B | $10.68B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Tempus AI (TEM) trades at $54.99, down 0.13% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed a narrower loss than expected and revenue beat, driving positive sentiment. The company is expanding through acquisitions like Personalis and launching new services, though it remains unprofitable with negative margins.
The outlook is cautiously optimistic due to revenue growth and strategic initiatives, but high valuation ratios and persistent losses pose risks. Upside is supported by a $61.57 consensus price target, while competitive and execution challenges require monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
